TYCOONSTORY’s Post

Innovation for respiratory relief. Respiratory conditions are a major health challenge worldwide, and innovative treatments are crucial for better care. Argentina-based Laboratorios Química Luar has developed a novel ibuprofen-based formula that can be inhaled as a mist, offering direct, targeted relief to the lungs. This nebulizable solution offers a new approach to managing complex respiratory conditions by reducing inflammation and improving respiratory function. Laboratorios Química Luar is one of the winners of the 2024 WIPO Global Awards that recognize exceptional SMEs and startups that make smart use of intellectual property for business and social impact. #WIPO #WIPOGlobalAwards #Argentina #Argentine #Invention #Innovation #IntellectualProperty #Technology #RespiratoryHealth #HealthcareInnovation #MedicalResearch #HealthTech

⚕🤖 Thrilled to be in Adelaide for the AusBiotech AusMedtech Annual Conference. All about Medtech Innovation and Colloaboration the next few days for myself and others. 📚 No better companion read other than the Medical Technology Association of Australia (MTAA) & MTPConnect "The Value of Medtech Report" launched last year with three key messages: ✨ MedTech supports the health of Australians ✨MedTech supports Australia’s innovation ✨MedTech contributes to the Australian economy 📈 Key Factors driving Australia's growing demands for medtech include: 1️⃣ Population growth: By 2050 there will be an estimated 36 million people living in Australia - an increase of ~12 million over the next three decades. 2️⃣ Ageing population: It is predicted that people aged 65+ will make up 22% of Australia’s population by 2057 or 8.8 million people. 3️⃣ Increase in chronic & degenerative disease: Nearly 50% of Australians have one or more chronic conditions, which are leading causes of illness, disability and death in Australia. 🏥 St Vincent's Hospital Melbourne team is on the ground connecting with current clients and new collaborators. Reach out to us for details on how we can assist with your clinical validation, ethics and governance review and clinical trials and collaboration opportunities. #artificialintelligent #AI #healthcare #medtech #digitalhealth #innovation #founders #startups #investment #VC #AusMedtech24 👍Like ♻Repost ⌨Comment &🔖Tag 22-23.v.2024

Last Masterclass of 2024 at the Cicada Innovations #HealthTechHub! Register below to attend and hear from a panel of experts on the delicate art of approaching investors

The latest BHI E-Newsletter is live with stories including: 🏭 MilliporeSigma Opens €290 Million Biosafety Testing Facility: A new facility in Rockville will enhance biosafety testing services amid growing global demand. 💰 SK bioscience Acquires Stake in Fina BioSolutions LLC: A $3 million investment makes SK bioscience the first strategic investor in the Rockville-based biotech firm. 🩸 AMPEL BioSolutions Launches Heart Disease Predictive Test: A new blood test aims to predict heart disease and support therapeutic interventions. 🏥 Children's National Hospital Ranks Among Best: The facility has earned a spot on the U.S. News & World Report Honor Roll for the eighth consecutive year. 💵 TEDCO Invests $100K in Mental Health Solutions Company: A recent investment in Person Care supports digital health initiatives for complex mental health conditions. 🌍 PQE Group Recognized for Business Excellence: The company has won the Best Managed Companies Award for the fourth consecutive year in Italy. 🤝 Children’s National-led Consortium Collaborates with European Partners: A new partnership aims to accelerate pediatric medical device innovation addressing rare diseases. 📈 J.P. Morgan's Q3 2024 Life Sciences VC Update: The report highlights strong healthcare investments, rising deal activity, and a revival in the exit market for VC-backed companies. https://lnkd.in/e88jD_Yn

🚀 We're gearing up for the presentation of the #BioRegionReport 2025! This presentation will kick off the #BCNHealthInnovation Week. Over 700 professionals attended last year's edition. Are you going to miss it? 📅 When: 17/02/25 📍 Where: Auditori l'Illa 👉 Register now: https://lnkd.in/demWi7At 📝 The #BioRegionCatalonia Report, published by #Biocat since 2009, has become the most solid and wide-reaching analysis of the assets, achievements and trends in the life sciences and healthcare sector in Catalonia within an international framework. 🔎 As we prepare for the 2024 edition, let’s take a moment to reflect on some of the standout achievements from the #BioRegionReport 2023, which highlighted Catalonia as one of the most dynamic and competitive hubs for health innovation in Europe: ✔ Health startups and scaleups in Catalonia raised €220 million in 2023. ✔ Catalonia ranks among the top 10 globally for clinical trial participation, placing 5th in Europe and 8th worldwide. ✔ Catalonia saw €1.025 billion in foreign investment—a 110% increase from the previous year, with the new AstraZeneca hub playing a key role in this growth. This event is proudly supported by our sponsors and collaborators, who are key to making the #BioRegionReport possible: Alira Health AstraZeneca Johnson & Johnson Menarini España Roche Amgen España Almirall ESTEVE Pfizer Sanofi ACCIÓ Catalonia.Health (CataloniaBio & HealthTech) Farmaindustria Fenin, Federación Española de Empresas de Tecnología Sanitaria

🚀 Aevice Health has successfully secured $7M in Seed Plus funding to revolutionize remote monitoring for chronic respiratory disease. This landmark investment, led by Coronet Ventures along with East Ventures, A&D Company, NTUitive, and SEEDS Capital, aims to propel Aevice Health's expansion across key markets such as the US, Japan, and Singapore. Aevice Health has been making significant strides in enhancing chronic respiratory disease management by developing one of the first remote monitoring solutions specifically for this purpose. With recent regulatory approvals and strategic partnerships, the company is well-positioned to impact the lives of millions suffering from chronic respiratory conditions. The introduction of their unique wearable stethoscope, which continuously monitors and analyses heart and lung sounds, affords healthcare providers the ability to make timely and informed clinical decisions. The new funding will not only fuel Aevice Health's product development but also bolster its market presence in key regions. As chronic respiratory disease remains the third leading cause of death globally, innovative solutions like those provided by Aevice Health are essential in ensuring patients can conveniently manage their health from the comfort of their homes. I'd love to hear your thoughts on this breakthrough. Please share your comments below! For further inquiries or collaboration opportunities, feel free to reach out to me directly at luke.mcclean@lifescirecruitment.com. #LifeSciences #HealthcareInnovation #RemoteMonitoring

Digital health technologies tackling some of Australia’s biggest health challenges are set to share a total funding injection of $3.25M from the Medical Research Future Fund (MRFF) 👏 The five companies are part of ANDHealth+, Australia's leading digital and connected health accelerator program. Since starting the program in August last year, they have received support from local and international advisors, experts and investors to strengthen their businesses, plus preliminary funding for key Stage 1 projects. The Stage 2 funding will help startups Eugene, Atmo Biosciences, Immunosis, Metabolic Health Solutions and Humanetix conduct further studies and scale their businesses to solve health challenges across genomics and genetic testing, gut and metabolic health, immune deficiencies and improving clinical efficiencies. ANDHealth CEO Bronwyn Le Grice said, “The funded projects will not only look at the commercial and clinical milestones these Australian health businesses need to meet, but provide expert support and advice, access to global partnerships and critical non-dilutive funding to ensure these solutions make it into the hands of patients, clinicians and care teams as swiftly as possible.” Read more: https://loom.ly/up_3puQ

Stay updated about the BioMan4r2 success stories!

Our President and General Manager, Christopher Stokes, spoke at this year’s Financial Times Global Pharma and Biotech Summit discussing the balance between access and innovation. He emphasised the need for a joined up, ecosystem approach to life sciences, and to evaluate the full social and economic value of medicines. Chris said, “The relationship between incentivising innovation and supporting access is often portrayed as a zero-sum game, but it doesn't have to be. Policies can be designed to encourage both. We need to acknowledge and address the true value that medicines bring to society as a whole. And our industry has an obligation to come to the table with information and evidence that supports this value.” As an industry, we know the pressures the healthcare system is facing, and we want to be part of the solution. Partnerships with industry are an important aspect of that. Through working in partnership, we hope to not only incentivise innovation and support equitable access but address the true impact of diseases on patients, their families, and the economy. #WeAreLillyUKandIreland

"The success or failure of a product is often decided before launch.” Dan Feldman, EVERSANA   The importance of defining a clear launch strategy was highlighted today through the fourth module within the 10xHealth scaleup program, focusing on market expansion and internationalisation. It is a pleasure to have a large group of experts – Mike Ryan, Edward Bellringer, David Byram, Venelin Milev, Alberta M.C. Spreafico, PhD, MBA, Dan Feldman, James May, and Marty Culjat from EVERSANA plus Mark Kroes from the company Global Data Support – share their deep insights during the one-day workshop with the 10xHealth participating companies. EVERSANA is an independent leading provider of global services to the life sciences industry. 🔬🌎   Insights from today’s module include: 👉 In-depth knowledge related to taking a life science product to the market, illustrated by real life cases and own experiences from several years in the industry.  👉 The crucial similarities and differences in launching in different markets, with special focus on the EU and the US complemented with some insights into Asia.  👉 The importance in having the complete picture in mind from the beginning, especially the commercial dimension, alongside product development and the path to regulatory approval.   #10xHealth is a scaleup program dedicated to supporting life science growth companies, and is jointly developed by SmiLe Venture Hub and Medicon Village with partial financing from the European Regional Development Fund. Companies participating in the 2024 10xHealth pilot include Uman Sense, Paindrainer AB, Iconovo AB, NanoEcho AB, Cyxone, and Neola Medical.   To find out more about 10xHealth: https://10xhealth.se/